|
Glaxo in-licenses Eisai’s Paritec in India
EPP News Bureau - Mumbai
GlaxoSmithKline Pharmaceuticals (GSK) has in-licensed Paritec
(rabeprazole sodium) from Eisai Pharmaceuticals India to co-promote it in India.
Paritec is a proton pump inhibitor discovered and developed by Eisai Co for
treating acid-related disorders like peptic ulcers and reflux gastric disorders.
Commenting on the development, S Kalyansundaram, managing director, GSK, said,
‘‘GSK has a strong presence in the gastro-intestinal market and enjoys
immense goodwill among the medical fraternity on account of Zantac.’’
|
The market size in this product segment is estimated
at Rs 80 crore out of the anti pepti ulcerant market of Rs 600 crore
|
Kalyansundaram declined to comment on the pricing of the product or on the
revenue it will generate.
The market size in this product segment is estimated at Rs
80 crore out of the anti pepti ulcerant market of Rs 600 crore. Analysts tracking
the sector said that there are 40 generic products in the same category currently
available in the market.
According to Hideshi Honda, executive officer and vice president
(global pharmaceuticals), Eisai Co, said, ‘‘We studied the Indian
market and decided to launch Paritec, one of our global blockbusters with worldwide
sales of 132 billion yen.’’ This is the second product out-licensed
by Eisai to a company in India The first was methycobal tablets and injections
to Wockhardt for nerve disorders.
|
